Diversify Wealth Management LLC Acquires 5,072 Shares of Gilead Sciences, Inc. $GILD

Diversify Wealth Management LLC boosted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 87.4% in the first quarter, HoldingsChannel reports. The fund owned 10,875 shares of the biopharmaceutical company’s stock after acquiring an additional 5,072 shares during the period. Diversify Wealth Management LLC’s holdings in Gilead Sciences were worth $1,401,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of GILD. Valmark Advisers Inc. lifted its holdings in shares of Gilead Sciences by 4.1% during the first quarter. Valmark Advisers Inc. now owns 3,283 shares of the biopharmaceutical company’s stock valued at $458,000 after purchasing an additional 130 shares during the last quarter. 180 Wealth Advisors LLC grew its stake in shares of Gilead Sciences by 1.7% in the 1st quarter. 180 Wealth Advisors LLC now owns 9,171 shares of the biopharmaceutical company’s stock worth $1,278,000 after buying an additional 151 shares during the last quarter. Fifth Third Bancorp grew its stake in shares of Gilead Sciences by 51.2% in the 1st quarter. Fifth Third Bancorp now owns 668,661 shares of the biopharmaceutical company’s stock worth $93,191,000 after buying an additional 226,510 shares during the last quarter. Glass Wealth Management Co LLC bought a new position in Gilead Sciences during the 1st quarter valued at approximately $257,000. Finally, Sovran Advisors LLC increased its position in Gilead Sciences by 16.6% during the 1st quarter. Sovran Advisors LLC now owns 7,843 shares of the biopharmaceutical company’s stock valued at $1,026,000 after buying an additional 1,115 shares in the last quarter. Institutional investors own 83.67% of the company’s stock.

Insider Buying and Selling at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $125.40, for a total value of $376,200.00. Following the completion of the sale, the chief financial officer directly owned 171,646 shares in the company, valued at $21,524,408.40. The trade was a 1.72% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 15,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $126.29, for a total transaction of $1,894,350.00. Following the transaction, the chief executive officer directly owned 607,133 shares of the company’s stock, valued at $76,674,826.57. The trade was a 2.41% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 77,000 shares of company stock worth $9,978,740. Company insiders own 0.30% of the company’s stock.

Gilead Sciences Stock Performance

GILD stock opened at $130.04 on Wednesday. The stock has a market capitalization of $161.45 billion, a PE ratio of 17.72 and a beta of 0.32. Gilead Sciences, Inc. has a 12-month low of $107.75 and a 12-month high of $157.29. The company has a current ratio of 1.97, a quick ratio of 1.77 and a debt-to-equity ratio of 0.89. The stock’s 50 day simple moving average is $129.72 and its 200 day simple moving average is $135.11.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 EPS for the quarter, beating the consensus estimate of $1.91 by $0.12. The business had revenue of $6.96 billion for the quarter, compared to the consensus estimate of $6.91 billion. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The company’s revenue was up 4.4% compared to the same quarter last year. During the same period last year, the business posted $1.81 EPS. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. As a group, research analysts forecast that Gilead Sciences, Inc. will post -0.79 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, June 29th. Shareholders of record on Monday, June 15th were given a $0.82 dividend. The ex-dividend date of this dividend was Monday, June 15th. This represents a $3.28 dividend on an annualized basis and a yield of 2.5%. Gilead Sciences’s payout ratio is 44.69%.

Wall Street Analyst Weigh In

Several research firms have commented on GILD. The Goldman Sachs Group boosted their target price on Gilead Sciences from $125.00 to $130.00 and gave the stock a “neutral” rating in a report on Friday, April 17th. Royal Bank Of Canada reduced their price target on Gilead Sciences from $122.00 to $120.00 and set a “sector perform” rating for the company in a report on Tuesday, July 7th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $155.00 price target on shares of Gilead Sciences in a research report on Monday, July 6th. Weiss Ratings cut shares of Gilead Sciences from a “buy (b)” rating to a “buy (b-)” rating in a research note on Thursday, May 28th. Finally, Rothschild & Co Redburn cut their price objective on shares of Gilead Sciences from $170.00 to $167.00 in a research report on Monday, May 11th. Twenty-six analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat, Gilead Sciences currently has an average rating of “Moderate Buy” and a consensus target price of $159.04.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.